http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Abbott Introduces Science-Based Nutrition Drinks to Help Patients Have a Better Recovery from Surgery
-
Abbott Reports First-Quarter 2017 Results
-
Abbott (ABT) to Acquire Alere (ALR) for $51/Share in Amended Agreement
-
Abbott and Alere Amend Terms of Merger Agreement
-
Abbott Hosts Conference Call for First-Quarter Earnings
-
Abbott (ABT) Reports Positive Data on Abbott's MitraClip® System Show Continued Benefit for People with Mitral Regurgitation, Most Common Heart Valve Disease
-
Abbott (ABT) Confirms Data Showing CardioMEMS HF System is Effective in Reducing Heart Failure Hospitalizations and Cost of Care
-
Late-Breaking Data Shows the CardioMEMS HF System is Effective in Reducing Heart Failure Hospitalizations and Cost of Care
-
Late-Breaking Data on Abbott's MitraClip® System Show Continued Benefit for People with Mitral Regurgitation, Most Common Heart Valve Disease
-
Abbott to Present at Barclays Capital 2017 Global Healthcare Conference
-
New Study Results May Lead to a New Standard of Care for In Vitro Fertilization Treatment
-
Abbott Announces Results of Early Tenders and Consents in Exchange Offers and Execution of Supplemental Indenture
-
Abbott Commences Exchange Offers and Consent Solicitations for St. Jude Medical, LLC Notes
-
Abbott Declares 373rd Consecutive Quarterly Dividend
-
Real-World Data from Abbott's FreeStyle® Libre Show Association Between Higher Frequency of Glucose Monitoring and Improved Glucose Control for People with Diabetes
-
Abbott (ABT) Announces FDA Grants First Commercial Authorization for Molecular Test to Detect Zika Virus Using Whole Blood
-
U.S. FDA Grants Abbott the First Commercial Authorization for a Molecular Test to Detect Zika Virus Using Whole Blood
-
Abbott (ABT) Receives U.S. Approval for Assurity MRI Pacemaker
-
Abbott Announces U.S. Approval for its Assurity MRI™ Pacemaker, the World's Smallest, Longest-Lasting Wireless MRI-Compatible Pacemaker
-
Abbott Reports Fourth-Quarter 2016 Results
-
New Study Demonstrates Spinal Cord Stimulation Can Reduce or Stabilize Opioid Use Among Chronic Pain Patients
-
Abbott Announces European Launch of the Proclaim™ DRG Neurostimulation System for the Management of Chronic Neuropathic Pain
-
New Data Confirms Abbott's Dorsal Root Ganglion Stimulation Offers Greater Treatment Success over Traditional Spinal Cord Stimulation
-
Abbott (ABT) Announces U.S. Launch of EnSite Precision Cardiac Mapping System
-
Abbott Announces U.S. Launch and First Commercial Use of the New EnSite™ Precision Cardiac Mapping System
-
Abbott (ABT) Blood and Plasma Screening System Alinity Gains CE Mark
-
Abbott Announces CE Mark for its Alinity ci-series Diagnostic Systems
-
Abbott Announces CE Mark for its "Alinity s" Blood and Plasma Screening System
-
Abbott Completes the Acquisition of St. Jude Medical
-
Abbott (ABT) Acquisition of St. Jude Medical (STJ) Close Date Set for January 4
-
Abbott Acquisition of St. Jude Medical Set to Close on January 4, 2017
-
Abbott Hosts Conference Call for Fourth-Quarter Earnings
-
Abbott to Present at J.P. Morgan Healthcare Conference
-
St. Jude Medical Announces Fourth Quarter Dividend
-
Abbott Raising Quarterly Dividend for 45th Straight Year
-
Abbott (ABT) Files Complaint to Terminate Alere (ALR) Acquisition
-
Abbott Seeks to Terminate Alere Acquisition
-
Study: Hospital Nutrition Program Shortens Patient Stays and Reduces Readmissions
-
Abbott Announces CE Mark for i-STAT Alinity, a Pioneering, Handheld Blood Testing Platform
-
Abbott (ABT) Receives Japan MHLW Approval of Absorb Heart Stent
-
Abbott's Absorb™ Bioresorbable Stent Approved as the First Fully Dissolving Heart Stent in Japan
-
A Great Place to Work, According to Science
-
St. Jude Medical (STJ) Shareholders Approve Abbott (ABT) Merger
-
St. Jude Medical Shareholders Approve Merger with Abbott
-
Abbott (ABT) Announces Publication of Positive Infant Formula with 2'-FL Human Milk Oligosaccharide+ Data
-
New Study: Babies Fed Infant Formula with 2'-FL Human Milk Oligosaccharide+ Had Immune Response More Like Breastfed Babies
-
Abbott Reports Third-Quarter 2016 Results
-
Abbott (ABT), St. Jude (STJ) Announce $1.12B Sale of Vascular Closure, Electrophysiology Businesses to Terumo
-
St. Jude Medical and Abbott to Sell Portion of Vascular Closure and Electrophysiology Businesses to Terumo Corporation
-
Abbott's (ABT) FreeStyle Libre Pro System Approved by U.S. FDA

